Premium
Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T‐cell receptor gene rearrangements
Author(s) -
Shimamoto Takashi,
Iguchi Tomotaka,
Ando Keiko,
Katagiri Tomoko,
Tauchi Tetsuzo,
Ito Yoshikazu,
Yaguchi Makoto,
Miyazawa Keisuke,
Kimura Yukihiko,
Masuda Michihiko,
Mizoguchi Hideaki,
Ohyashiki Kazuma
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02925.x
Subject(s) - hypoplasia , myelodysplastic syndromes , gene rearrangement , immunology , biology , medicine , cancer research , gene , genetics , bone marrow
Myelodysplastic syndrome (MDS) with erythroid hypoplasia, a rare form of MDS, has not yet been clearly defined. We report four patients with MDS with erythroid hypoplasia who received immunosuppressive therapy. All were elderly, had severe transfusion‐dependent anaemia, morphological evidence of myelodysplasia and a low percentage (3·2–13·6%) of erythroid precursors. Administration of cyclosporin A (CsA) improved their anaemia; all transfusion‐dependent patients achieved transfusion‐independence. An inverted CD4/8 ratio was seen in three patients who also demonstrated T‐cell receptor (TCR)‐β and ‐γ gene rearrangements by Southern blotting and clonality by polymerase chain reaction. Treatment with CsA can be an attractive alternative treatment for patients with MDS with erythroid hypoplasia, which may be associated with a clonal abnormality in T cells.